

## » PŘEHLEDOVÉ ČLÁNKY

OCRELIZUMAB – CO VÍME, CO MŮŽEME ZLEPŠIT NYNÍ A CO V BUDOUCNU

on in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression. *J Neurol*. 2022;269(10):5443-5453.

8. Hartung HP, Berger T, Bermel R, et al. Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. *Mult Scler Relat Disord*. 2020;46:102492.

9. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. *N Engl J Med*. 2017;376(3):221-234.

10. Hauser SL, Bar-Or A, Weber MS, et al. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. *Neurol-Neuroimmunol Neuroinflammation*. 2023;10(2):e200094.

11. He A, Merkel B, Brown JW, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *Lancet Neurol*. 2020;19(4):307-316.

12. Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated

Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. *Jama Neurol*. 2020;77(9):1132-1140.

13. Kempen ZL van, Hogenboom L, Killestein J. Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO. *Mult Scler J*. 2022;28(5):693-695.

14. Kister I, Oh C, Douglas EA, et al. No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis. *Neurol Clin Pr*. 2023;13(5):e200185.

15. Montalban X, Matthews PM, Simpson A, et al. Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review. *Ann Clin Transl Neuro*. 2023;10(3):302-311.

16. Pfeuffer S, Rolfes L, Ingwersen J, et al. Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab. *Neurology Neuroimmunol Neuroinflammation*. 2023;10(3):e200104.

17. Song A, Hendricks R, Chung S, et al. Immunogenicity with Repeated Dosing of Ocrelizumab in Patients with Mul-

tipl Sclerosis (P2.087) *Neurology Apr* 2016, 86 (16 Supplement) P2.087. Available form: [https://n.neurology.org/content/86/16\\_Supplement/P2.087](https://n.neurology.org/content/86/16_Supplement/P2.087).

18. Toorop AA, Lierop ZYGJ van, Strijbis EMM, et al. The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis. *Mult Scler Relat, Dis*. 2022;57:103364.

19. Torres J, Roodselaar J, Sealey M, et al. Distribution and Efficacy of Ofatumumab and Ocrelizumab in Humanized CD20 Mice Following Subcutaneous and Intravenous Administration. *Front Immunol*. 2022;13:814064.

20. Vermersch P, Oreja-Guevara C, Siva A, et al. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3 b CASTING single-arm, open-label trial. *Eur J Neurol*. 2022;29(3):790-801.


21. Zecca C, Bovis F, Novi G, et al. Treatment of multiple sclerosis with rituximab: a multicentric Italian-Swiss experience. *Mult Scler J*. 2019;26(12):1519-1531.



# 4.

## dny praktické neurologie

3.–4. 10. 2024  
ÚSTÍ NAD LABEM



VÍCE INFORMACÍ NA  
[www.kongresneurologie.cz](http://www.kongresneurologie.cz)

